Pfizer has announced it is developing a new formulation of its famous mRNA vaccine for a COVID booster dose.


First published in July 2021.


US drugmaker Pfizer and its German partner BioNTech have claimed that there is more and more evidence that fully vaccinated people’s immunity starts to wane six months after receiving their second dose. In a statement to CNN on Thursday, Pfizer explained:

“As seen in real-world data released from the Israel Ministry of Health, vaccine efficacy in preventing both infection and symptomatic disease has declined six months post-vaccination, although efficacy in preventing serious illnesses remains high.

PMP Xtra

Israel’s Health Ministry released data on Monday showing that the Pfizer-BioNTech COVID vaccine appears to largely prevent hospitalization and serious cases, but is significantly less effective against preventing the spread of the Delta variant of the coronavirus.
According to the ministry, the Pfizer vaccine’s effectiveness in preventing symptomatic COVID-19 has dropped by some 30% to 64%, given the spread of the Delta variant. The data shows that during May, when the strain was less prevalent, the vaccine was 94.3% effective.

(Source ▪ The Times of Israel)

“Additionally, during this period the Delta variant is becoming the dominant variant in Israel as well as many other countries. These findings are consistent with an ongoing analysis from the Companies Phase 3 study.

“While protection against severe disease remained high across the full six months, a decline in efficacy against symptomatic disease over time and the continued emergence of variants are expected. Based on the totality of the data they have to date, Pfizer and BioNTech believe that a third dose may be beneficial within 6 to 12 months following the second dose to maintain highest levels of protection.”

Pfizer added that it is already developing a new formulation of its famous mRNA vaccine, BNT162b2, for a booster dose that could protect people better from new variants, in particular the Delta variant.

“While Pfizer and BioNTech believe a third dose of BNT162b2 has the potential to preserve the highest levels of protective efficacy against all currently known variants including Delta, the companies are remaining vigilant and are developing an updated version of the Pfizer-BioNTech COVID-19 vaccine that targets the full spike protein of the Delta variant.

“The first batch of the mRNA for the trial has already been manufactured at BioNTech’s facility in Mainz, Germany. The Companies anticipate the clinical studies to begin in August, subject to regulatory approvals.” 




— AUTHOR —

PMP News reporting.


GET THEM INVOLVED:


Going Further:



[This piece was first published in PMP Magazine on 11 July 2021. | The author writes in a personal capacity.]

(Cover: Flickr/U.S. Secretary of Defense. / Licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.)

Creative Commons License